GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » Net Income

WuXi XDC Cayman (HKSE:02268) Net Income : HK$642 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. WuXi XDC Cayman's Net Income for the six months ended in Jun. 2024 was HK$526 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was HK$642 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. WuXi XDC Cayman's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was HK$0.41.


WuXi XDC Cayman Net Income Historical Data

The historical data trend for WuXi XDC Cayman's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Net Income Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Income
31.18 67.26 173.91 310.13

WuXi XDC Cayman Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Income Get a 7-Day Free Trial 115.19 64.17 193.83 116.30 525.60

WuXi XDC Cayman Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

WuXi XDC Cayman's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=393.336+-83.208+0+-5.6843418860808E-14
=310

WuXi XDC Cayman's Net Income for the quarter that ended in Jun. 2024 is calculated as

Net Income(Q: Jun. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=604.712+-79.113+0+1.1368683772162E-13
=526

Net Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$642 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi XDC Cayman  (HKSE:02268) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

WuXi XDC Cayman's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


WuXi XDC Cayman Net Income Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi XDC Cayman Business Description

Comparable Companies
Traded in Other Exchanges
Address
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.
Executives
Wuxi Biologics (cayman) Inc. 2101 Beneficial owner
Wuxi Apptec Co., Ltd.
Shang Hai He Quan Yao Ye Gu Fen You Xian Gong Si
He Quan Yao Ye Xiang Gang Tou Zi You Xian Gong Si
Shang Hai Yao Ming Kang De Xin Yao Kai Fa You Xian Gong Si

WuXi XDC Cayman Headlines

No Headlines